体外研究 (In Vitro) |
AH057 (1 μM; 2 h) 在 HeLa 细胞中选择性抑制 p-JAK2、p-STAT3,不影响 p-AKT、p-p65 蛋白磷酸化。
AH057 (0.1-20 μM; 2 h) 剂量依赖性抑制 HeLa、DU145、HepG2 细胞 JAK2/STAT3 磷酸化,其中宫颈癌细胞 HeLa 敏感性最高。
AH057 (HeLa 1 μM, DU145 10 μM, HepG2 20 μM; 0.25-3 h) 时间依赖性抑制 JAK2 和 STAT3 活化,并在 15 min 内快速抑制 JAK2 磷酸化。
AH057 (预处理 1 h; 随后使用 250 ng/mL IL-6 或 IFN-α 共刺激 1 h) 在 HeLa、DU145 和 HepG2 可阻断 IL-6、IFN-α、IFN-γ 刺激引起的 JAK1/JAK2/TYK2、STAT1/STAT3 磷酸化激活。
AH057 (预处理 1 h; 随后使用 250 ng/mL IL-6 或 IFN-α 共刺激 4 h) 在 HeLa、DU145 和 HepG2 下调 IL-6 诱导的 SOCS3,和IFN-α 诱导的 IRF1 和 IRF2 mRNA 表达。
AH057 (20 μM; 4 h) 抑制过表达 JAK1/JAK2/TYK2 激酶 JH1 结构域的 HEK293T 细胞总酪氨酸磷酸化及 STAT1/STAT3 活化。
AH057 (0.0005-100 μM; 72 h) 抑制多种癌细胞系活力,其中宫颈癌细胞系 HeLa、CaSki 和 SiHa 的 IC50 分别为 0.62 μM、11.28 μM 和 17.53 μM。
AH057 (0.2-100 μM;48 h) 抑制 HeLa、CaSki、SiHa 宫颈癌细胞侵袭能力,对正常 HcerEpic 细胞无明显抑制作用。
AH057 (125-250 nM;14 天) 剂量依赖性减少宫颈癌细胞克隆形成数量。
AH057 (200 nM, 10 μM) 体外抑制宫颈癌细胞 (Hela, CaSki) 划痕迁移能力。
AH057 (0.5-20 μM;24 h) 诱导 HeLa、CaSki 细胞凋亡与 G1/S 周期阻滞;HeLa 细胞 G1 期比例从对照组 69.95% 上升至 1 μM 处理组 81.9%。
AH057 (500 nM + SGI-1027 (MS-W68225) 1 μM;24 h) 联合 SGI-1027 在 HeLa 细胞中产生协同凋亡与更强 G1 期阻滞,进一步下调 Cyclin D1/A2/B1、Bcl-XL、Survivin,上调活化 Caspase-3 与裂解 PARP,联合治疗表现出某些基因(BAX、BCL-XL、BCL-2、MDM2、Cyclin A2、Cyclin D3 和 CDK2)的协同下调。
AH057 通过基于 docking 的虚拟筛选被鉴定为 JAK 抑制剂候选物,分子对接显示 AH057 可结合 JAK2 活性位点口袋,并通过疏水相互作用以及与 Tyr931 和 Leu932 等关键残基形成氢键发挥结合作用。
Western Blot Analysis
| Cell Line: |
HeLa |
| Concentration: |
10 μM |
| Incubation Time: |
4 h |
| Result: |
Showed the strongest inhibitory activity among nine top-ranking compounds against JAK2 phosphorylation and STAT3 phosphorylation.
Reduced pTyr1007/1008-JAK2 and pTyr705-STAT3 levels while maintaining total JAK2 and STAT3 protein levels.
|
Western Blot Analysis
| Cell Line: |
HeLa, DU145, HepG2 |
| Concentration: |
HeLa (0.1, 0.5, 1.0, 1.5, 2.0 μM); DU145, HepG2 (1, 5, 10, 15, 20 μM) |
| Incubation Time: |
2 h |
| Result: |
Reduced pTyr1007/1008-JAK2, pTyr705-STAT3 and pSer727-STAT3 levels in a dose-dependent manner.
HeLa cells showed higher AH057 sensitivity than DU145 and HepG2 cells.
Reduced JAK2 and STAT3 phosphorylation in both DU145 and HepG2 cells, confirming inhibition of JAK2/STAT3 signaling across multiple cancer cell lines.
|
Western Blot Analysis
| Cell Line: |
HeLa, DU145, HepG2 |
| Concentration: |
1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells |
| Incubation Time: |
0.25, 0.5, 1, 2, 3 h |
| Result: |
Time-dependently inhibited JAK2 and STAT3 activation.
Rapidly reduced JAK2 phosphorylation within 15 min, supporting direct inhibition of JAK2 kinase activity.
|
Western Blot Analysis
| Cell Line: |
HeLa, DU145, HepG2 |
| Concentration: |
1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells |
| Incubation Time: |
1 h pretreatment; IL-6, IFN-α or IFN-γ stimulation at 250 ng/mL for 1 h |
| Result: |
Blocked IL-6-induced JAK1, JAK2 and STAT3 phosphorylation.
Decreased IFN-α-induced JAK1, JAK2, TYK2, STAT1 and STAT3 phosphorylation.
Reduced IFN-γ-induced JAK1, JAK2, STAT1 and STAT3 phosphorylation.
|
Real Time qPCR
| Cell Line: |
HeLa, DU145, HepG2 |
| Concentration: |
1 μM in HeLa cells; 10 μM in DU145 cells; 20 μM in HepG2 cells |
| Incubation Time: |
1 h pretreatment; IL-6, IFN-α or IFN-γ stimulation at 250 ng/mL for 4 h |
| Result: |
Suppressed IL-6-induced SOCS3 mRNA transcription and IFN-α-induced IRF1 mRNA transcription in all three cell lines. |
Western Blot Analysis
| Cell Line: |
HEK293T cells overexpressing JAK1-JH1, JAK2-JH1 or TYK2-JH1 |
| Concentration: |
20 μM |
| Incubation Time: |
4 h |
| Result: |
Reduced total tyrosine phosphorylation driven by overexpressed JAK1-JH1, JAK2-JH1 or TYK2-JH1.
Suppressed downstream STAT1 and STAT3 phosphorylation, supporting direct inhibition of JAK kinase domains.
|
Cell Viability Assay
| Cell Line: |
HcerEpic, HeLa, CaSki, SiHa, SK-OVR-3, ES-2, BT549, Huh7, Hep3B, HepG2, DU145, NCI-87, AGS, AsPC-3, U251 |
| Concentration: |
0.0005-100 μM |
| Incubation Time: |
72 h |
| Result: |
Inhibited the viability of multiple cancer cell lines.
HeLa cells were the most sensitive tested cancer cells, with an IC50 of 0.62 μM.
CaSki and SiHa cervical cancer cells showed IC50 values of 11.28 μM and 17.53 μM, respectively.
Other cancer cell lines showed IC50 values ranging from 14.06 μM to 48.96 μM.
|
Cell Invasion Assay
| Cell Line: |
HcerEpic, HeLa, CaSki, SiHa |
| Concentration: |
100 μM in HcerEpic cells; 200 nM in HeLa cells; 10 μM in CaSki and SiHa cells |
| Incubation Time: |
48 h |
| Result: |
Impaired invasion ability of HeLa, CaSki and SiHa cervical cancer cells.
Did not significantly reduce invasion of normal HcerEpic cells under the tested condition.
|
Cell Proliferation Assay
| Cell Line: |
HcerEpic, HeLa, CaSki, SiHa |
| Concentration: |
50, 100 μM in HcerEpic cells; 125, 250 nM in HeLa cells; 1, 5 μM in CaSki and SiHa cells |
| Incubation Time: |
14 days |
| Result: |
Dose-dependently reduced colony formation in HeLa, CaSki and SiHa cervical cancer cells.
Did not significantly reduce colony formation of normal HcerEpic cells at 50 μM or 100 μM.
|
Cell Viability Assay
| Cell Line: |
HeLa |
| Concentration: |
500 nM; 1 μM SGI-1027 (MS-W68225) |
| Incubation Time: |
48 h |
| Result: |
Synergistically reduced HeLa cell viability.
The combined effect of AH057 and SGI-1027 was time-dependent, and combination treatment induced stronger cell death than either single compound.
|
Apoptosis Analysis
| Cell Line: |
HeLa |
| Concentration: |
500 nM; 1 μM SGI-1027 (MS-W68225) |
| Incubation Time: |
4 h |
| Result: |
Increased both early and late apoptotic cell populations.
Combination treatment induced a higher percentage of apoptotic cell death than either AH057 or SGI-1027 alone.
|
Western Blot Analysis
| Cell Line: |
HeLa |
| Concentration: |
500 nM; 1 μM SGI-1027 (MS-W68225) |
| Incubation Time: |
24 h |
| Result: |
Enhanced cleaved PARP and cleaved caspase-3 levels.
Reduced the anti-apoptotic proteins Bcl-XL and Survivin, with stronger effects under combination treatment than either single compound.
Decreased Cyclin D1, Cyclin A2 and Cyclin B1 protein levels.
Combination treatment further potentiated the decrease in these cell-cycle regulators compared with AH057 alone.
|
Cell Cycle Analysis
| Cell Line: |
HeLa |
| Concentration: |
500 nM; 1 μM SGI-1027 (MS-W68225) |
| Incubation Time: |
24 h |
| Result: |
Induced G1/S cell-cycle arrest. SGI-1027 alone increased S-phase accumulation, whereas combination treatment induced a higher G1-phase population than either single compound. |
|